MENU

Evolution of a Platform-Based Non-Clinical Safety Assessment Approach for Vaccines

C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

Platform based therapeutics and vaccines offer a unique opportunity to simplify and streamline the drug development process.  Moderna has taken the approach of harnessing the power of mRNA as a platform to instruct the body to produce its own therapeutic proteins and antigens against infectious diseases.  However, mRNA is very labile and effective delivery requires the utilization of lipid nanoparticles (LNPs).  Some LNPs deliver extensively to antigen presenting cells making them excellent candidates for delivery of mRNA encoding infectious disease targets to generate an immune response.  Since these LNPs and mRNA composition differ little regardless of infectious agent to be treated the general assessments of these candidates non-clinically can be standardized and a platform approach was hypothesized.  The assessment of mRNA-based vaccines required the assessment of both the delivery system (genotoxicity and biodistribution) and safety (Drug product and immune response to antigens produced) as is standard in the evaluation of vaccine candidates.  However, we generated a broad dataset and achieved Health Authority agreement that a platform-based approach could be used to undertake First in Human testing.  This allowed for rapid responses to potential infectious threats such as SARS-CoV-2.  Using this approach, we were able to move from viral sequence to First in human dosing in a mere 63 days demonstrating the high utility of this approach to enhance responses to infectious threats and endemic diseases.

Learning Objective:

1. Understand the basic premise of platform-based vaccines and the benefits of this approach

2. Learning the underlying science behind a platform-based safety assessment


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
OCT 27, 2021 8:00 AM PDT
C.E. CREDITS
OCT 27, 2021 8:00 AM PDT
Date: October 27, 2021 Time: 8:00am (PDT), 11:00am (EDT) Learn about how brightfield images can take your flow cytometry data to the next level. Join Dr. Cora Chadick, Technical Director, as...
MAY 18, 2021 8:00 AM PDT
C.E. CREDITS
MAY 18, 2021 8:00 AM PDT
Date: May 18, 2021 Time: 8:00am (PST) The global pandemic has caused an increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provide qu...
Loading Comments...
Show Resources